Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)
Mené sur 9 patientes atteintes d'un cancer du sein HER2-, cet essai de phase I évalue la dose maximale recommandée du nintedanib en complément d'une chimiothérapie de référence
Introduction: Previous small-molecule antiangiogenics have compromised chemotherapy dose intensity in breast cancer. We present a phase I trial of a novel selective agent, nintedanib, plus standard chemotherapy in early breast cancer.
Methods: Her-2-negative breast cancer patients with tumours larger than 2 cm were eligible for dose-escalation trial (classic 3+3 method).
Results: The recommended phase II dose (RP2D) was 150 mg BID of nintedanib combined with standard dose of weekly paclitaxel followed by adriamycin plus cyclophosphamide. The dose-limiting toxicity was transaminase elevation. At the RP2D, the dose intensity was ~100%. The pathologic complete response was 50%.
Conclusions: The combination allows the delivery of full-dose intensity, while efficacy seems promising.
British Journal of Cancer , résumé, 2013